Benchmark Report - Discover the state of R&D Digitalization in 2026
Having digitized (from paper to glass) through the late 1990s and early 2010s, the R&D community is now navigating the early adoption of digitalization and digitally enhanced workflows.
Now available as a free download, this report from ACD/Labs addresses the state of the laboratory digitalisation process in 2026. While many organisations have digitised their data, obstacles to effective use of this information remain in place. Uncover the progress, pitfalls and perks of digitalisation across today's R&D landscape.
Drawing on collective insights from an audience of over 100 global organisations - including Bayer, GSK, Sanofi, Novartis, J&J, Eli Lilly, Unilever, Procter & Gamble, FMC, Chemours and many more - the report reveals key insights such as:
- The disparity between current high priorities (AI/ML adoption) and how many organisations still struggle to centralise and digitalise the data needed to achieve these goals
- The concept of 'digitalisation maturity' - the gap between strategic intent and reality for many
- Why centralising data benefits organisations, powering the next generation of discovery and development.
Discover trends based on feedback from leading organisations:
- Market leaders in pharma
- Consumer goods giants and specialty chemicals companies
- Regulatory organisations (US Pharmacopeia, Health Canada)
- Academic research groups
Explore in detail:
- Where the demand for digitalisation now arises - in harnessing data for AI/ML models and beyond
- Why many organisations struggle to achieve it - and the factors that cause these common delays
- How to make existing digitalisation more coherent - automating workflows, integrating systems, and reducing the burden of manual management
Discover the state of digitalisation today. Download the full report below to find out more.